ISE:OVXA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ovoca Bio plc, a bio-technology company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Ovoca Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVXA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.2%

OVXA

-0.2%

IE Pharmaceuticals

7.3%

IE Market


1 Year Return

176.0%

OVXA

16.3%

IE Pharmaceuticals

5.9%

IE Market

Return vs Industry: OVXA exceeded the Irish Pharmaceuticals industry which returned 16.9% over the past year.

Return vs Market: OVXA exceeded the Irish Market which returned 5.3% over the past year.


Shareholder returns

OVXAIndustryMarket
7 Day6.2%-0.2%7.3%
30 Day15.0%-1.4%18.8%
90 Day25.5%5.4%3.5%
1 Year176.0%176.0%20.1%16.3%7.2%5.9%
3 Year38.0%38.0%26.8%12.2%10.9%5.8%
5 Year66.3%66.3%30.9%8.3%40.8%30.4%

Price Volatility Vs. Market

How volatile is Ovoca Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ovoca Bio undervalued compared to its fair value and its price relative to the market?

0.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OVXA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OVXA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OVXA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: OVXA is unprofitable, so we can't compare its PE Ratio to the Irish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVXA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVXA is good value based on its PB Ratio (0.5x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Ovoca Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ovoca Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Ovoca Bio performed over the past 5 years?

49.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVXA is currently unprofitable.

Growing Profit Margin: OVXA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVXA is unprofitable, but has reduced losses over the past 5 years at a rate of 49.6% per year.

Accelerating Growth: Unable to compare OVXA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVXA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).


Return on Equity

High ROE: OVXA has a negative Return on Equity (-9.24%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ovoca Bio's financial position?


Financial Position Analysis

Short Term Liabilities: OVXA's short term assets (€3.5M) exceed its short term liabilities (€122.0K).

Long Term Liabilities: OVXA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OVXA is debt free.

Reducing Debt: OVXA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if OVXA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OVXA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Ovoca Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVXA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVXA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVXA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVXA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVXA's dividend in 3 years as they are not forecast to pay a notable one for the Irish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average board tenure


CEO

Kirill Golovanov (41yo)

8.08yrs

Tenure

€164,000

Compensation

Mr. Kirill Golovanov has been the Chief Executive Officer at Ovoca Bio plc (formerly known as Ovoca Gold plc) since May 2012. Mr. Golovanov has been Corporate Secretary of Ovoca Bio plc (formerly known as  ...


CEO Compensation Analysis

Compensation vs Market: Kirill's total compensation ($USD0.00) is below average for companies of similar size in the Irish market ($USD325.59K).

Compensation vs Earnings: Kirill's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Mikhail Alexandrovich Mogutov
Executive Chairman 12.42yrs€106.00kno data
Kirill Golovanov
CEO, Company Secretary & Executive Director8.08yrs€164.00k23.92% 2.7m
Christopher Wiltshire
Interim Chief Business Officer & Non-Executive Director1.92yrsno datano data
Leonid Skoptsov
Non-Executive Director14yrs€106.00k14.29% 1.6m
Timothy McCutcheon
Independent Non-Executive Director11.42yrs€16.00kno data
Romulo Colindres
Non-Executive Director1.92yrsno datano data

9.8yrs

Average Tenure

53.5yo

Average Age

Experienced Board: OVXA's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ovoca Bio plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ovoca Bio plc
  • Ticker: OVXA
  • Exchange: ISE
  • Founded: 1985
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €11.256m
  • Shares outstanding: 81.56m
  • Website: https://ovocabio.com

Number of Employees


Location

  • Ovoca Bio plc
  • 17 Pembroke Street Upper
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVXAISE (Irish Stock Exchange)YesOrdinary SharesIEEURJan 1992
OVBAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJan 1992
OVXADB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992

Biography

Ovoca Bio plc, a bio-technology company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing Libicore, a medication for treatment of female sexual dysfunction. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 20:55
End of Day Share Price2020/06/04 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.